PhaseV, a Tel Aviv, Israel and Boston, MA-based company specializing in causal machine learning (ML) technology for optimizing clinical trial design and analysis, raised $15 million in funding.
SaaS Investors
The round was led by Viola Ventures and Exor Ventures, with participation from LionBird and a group of prominent angel investors.
Viola Ventures is a venture capital firm, that empowers early-stage start-ups to become global category leaders. Founded in 2000, Viola Ventures manages over $1.35B, with a focus on early-stage tech investments (seed and A).
Exor Ventures is the early-stage investment arm of Exor. They invest in early-stage companies. Exor Ventures was founded in 2018 and is based in New York, New York.
PhaseV Use of Funds
The company will use the funds to further advance its platform and expand its reach to additional pharma, CRO, and biotech companies in Europe and the U.S.
PhaseV Use of Funds
Founded by Elad Berkman and Dr. Raviv Pryluk, PhaseV develops a platform for adaptive clinical trial design and closed-loop execution, leveraging an intuitive user interface and flexible software. PhaseV uses advanced causal inference to detect hidden signals in clinical data and provide actionable insights for clinical development teams. The company's ML-driven approach allows for retrospective analysis and optimal design of clinical trials, potentially accelerating the drug development process and improving the chances of success. PhaseV serves various therapeutic areas, including oncology, endocrinology, autoimmune diseases, and rare diseases.
Funding Details
Company: PhaveV Trials Ltd.
Raised: $15.0M
Round: Unknown
Funding Month: October 2023
Lead Investors: Viola Ventures and Exor Ventures
Additional Investors: LionBird
Company Website: https://phasevtrials.com/
Software Category: Clinical Trial Optimization
Source: https://www.prnewswire.com/news-releases/phasev-raises-15-million-to-push-the-boundaries-of-ml-for-clinical-trial-optimization-301965707.html